Lipodystrophy in 685 HIV-1–Treated Patients: Influence of Antiretroviral Treatment and Immunovirological Response

REFERENCES

• Panda FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997;11:1731–1738.
   PubMed Web of Science ®Google Scholar
• Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in ad-vanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351:543–549.
   PubMed Web of Science ®Google Scholar
• Mezzaroma I, Carlesimo M, Pinter E, et al. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis. 1999;29:1423–1430.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725–733.
   PubMed Web of Science ®Google Scholar
• Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommenda-tions of the International AIDS Society-USA Panel. JAMA. 1997;277:1962–1969.
   PubMed Web of Science ®Google Scholar
• Miller KK, Daly PA, Sentochnik JD, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;27:68–72.
   PubMed Web of Science ®Google Scholar
• Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS. 1998;12:F37–F39.
   PubMed Web of Science ®Google Scholar
• Lo JC, Mulligan K, Tai WV, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;351:867–870.
   PubMed Web of Science ®Google Scholar
• Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet. 1997;350:1596.
   PubMed Web of Science ®Google Scholar
• Herry I, Bernard L, de Truchis P, Perronne C. Hypertrophy of the breasts in a patient with indinavir. Clin Infect Dis. 1997;25:937–938.
   PubMed Web of Science ®Google Scholar
• Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal fat accumulation associated with use of indinavir. Lancet. 1998;351:871–875.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58.
   PubMed Web of Science ®Google Scholar
• Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493–2505.
   PubMed Web of Science ®Google Scholar
• Williamson K, Reboli AC, Manders SM. Protease inhibitor-induced lipodystrophy. J Am Acad DermatoL 1999;40:635–636.
   PubMed Web of Science ®Google Scholar
• Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr. 1999;21:107–113.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Mantzoros C, Hammer S, Samore M. Effect of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med. 2000;160:2050–2056.
   PubMed Web of Science ®Google Scholar
• Shaw AJ, McLean KA, Evans BA. Disorders of fat distribution in HIV infection. Int J STD AIDS. 1998;9:595–599.
   PubMed Web of Science ®Google Scholar
• Domingo P, Mathias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS. 1999;13:2261–2267.
   PubMed Web of Science ®Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study. AIDS. 2000;14:37–49.
   PubMed Web of Science ®Google Scholar
• Lc JO, Mulligan K, Tai VW, Algren H, Schambelan M. Body shape changes in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retroyirol. 1998;19:307–308.
   PubMedGoogle Scholar
• Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465–471.
   PubMed Web of Science ®Google Scholar
• Madge S, Kinlochde-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS. 1999;13:735–737.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Thorisdottir A, Kauffman GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyper-lipidemia, and diabetes mellitus: A cohort study. Lancet. 1999;353:2093–2099.
   PubMed Web of Science ®Google Scholar
• Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet. 2001;357:592–598.
   PubMed Web of Science ®Google Scholar
• Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment data-base. AIDS. 2001;15:231–239.
   PubMed Web of Science ®Google Scholar
• Kravcik S. HIV lipodystrophy: A review. HIV Clin Trials. 2000;1(3):37–50.
   PubMedGoogle Scholar
• Montessori V, Heath V, Yip B, et al. Predictors of adherence with triple combination antiretroviral therapy. In: Seventh Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, CA. Abstract 72.
   Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659–1667.
   PubMed Web of Science ®Google Scholar
• Carr A, Miller J, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25–F32.
   PubMed Web of Science ®Google Scholar
• Joly V, Flandre P, Meiffredy S, et al. Assessment of lipodystrophy in patient previously exposed to AZT, ddl or ddC, but naive for d4T and protease inhibitors (P1), and randomised between d4T/3TC/Indinavir and AZT/3TC/ Indinavir (NOVAVIR trial). In: Eighth Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago IL. Oral Session 64, Abstract 72.
   Google Scholar
• Molina JM, Chene G, Ferchal F, et al. The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. J Infect Dis. 1999;180:351–358.
   PubMed Web of Science ®Google Scholar
• Goujard C, Boufassa F, Deveau C, Laskri D, Meyer L. Incidence of clinical lipodystrophy in HIV-1-infected patients treated during primary infection. Reseach letters. AIDS. 2001;15(2):282–284.
   PubMed Web of Science ®Google Scholar
• Gharakhanian S. The HIV-associated lipodystrophy syndrome: Research, results, yet more questions. Editorial comment. AIDS. 200115: 271–273.
   Google Scholar
• Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. CID. 2001;32:130–139.
   PubMed Web of Science ®Google Scholar